The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects.
about
Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infectionsA Review of the Toxicologic Implications of ObesityDosing of antibacterial agents in obese adults: does one size fit all?Pharmacokinetics of Antimicrobials in Obese Children.Musculoskeletal safety outcomes of patients receiving daptomycin with HMG-CoA reductase inhibitors.Prospective, open-label investigation of the pharmacokinetics of daptomycin during cardiopulmonary bypass surgery.Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections.A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections.Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin.Therapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology.Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing.An approach to evaluating drug-nutrient interactions.Update on daptomycin: the first approved lipopeptide antibiotic.Antimicrobial Stewardship Intervention and Feedback to Infectious Disease Specialists: A Case Study in High-Dose Daptomycin.Normalization of creatine kinase values in a case of rhabdomyolysis during daptomycin treatmentAntimicrobial dosing considerations in obese adult patients.Daptomycin pharmacokinetics in adult oncology patients with neutropenic feverDaptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes.The effects of obesity on drug pharmacokinetics in humans.Impact of obesity on drug metabolism and elimination in adults and children.Daptomycin dosing strategies in patients receiving thrice-weekly intermittent hemodialysis.Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review.Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options).Effect of Daptomycin Dose on the Outcome of Vancomycin-Resistant, Daptomycin-Susceptible Enterococcus faecium Bacteremia.β-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus.Successful treatment of infective panniculitis with daptomycin in a pregnant, morbidly obese patient.Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme.Using vancomycin concentrations for dosing daptomycin in a morbidly obese patient with renal insufficiency.No role for patient body weight on renal function assessment for drug dosing.
P2860
Q26752922-CF996341-350C-4D6E-A6D7-2043CC7DDD92Q28082947-5A9AFC19-CE25-4CA7-B49E-163B365F12E7Q30362353-88DC7157-3CA4-4B50-B9DC-32B53D7AB90AQ33855312-61218171-83E7-4717-B310-5AD531A0B5EEQ34298999-D05BE939-8C9C-420F-B70F-DAE726D8297FQ35004882-20F92942-C00F-4DBD-8FA9-32FA20249653Q35065838-3926D018-2D10-446E-A7E6-2AD3FA0C258CQ35166807-61F62B53-AAD9-424E-8C94-706B9E1B82B4Q35912780-71DC8F28-C6FA-443D-B3F2-69023333299FQ35959546-A5B8502A-CFA2-4D9B-9D11-BC1D256A3F63Q36111191-FB698D89-94E6-46B2-87E9-ECBAF0BBEAABQ36247129-74B092CA-95A8-44DB-8F68-3C044F11F1A8Q36320632-210F63F0-35DC-43A5-9A26-69108629BF0CQ36521880-3DB4CC7B-3ECA-450A-9483-B774BC432710Q36683458-56A6FB31-7A41-496D-8DF0-FC30F6680214Q36865495-586DF6AD-087C-4FDF-93BE-E7B7519B748EQ36892796-B1B25DA1-95FB-4537-944F-96C85E638A58Q37072100-8CDAF070-5925-4534-B759-11CA0C64D579Q37544510-AD4CC7F4-B9E0-465B-B340-4E28AFCA45F7Q37854751-0028489B-1C14-411D-A0B9-EAF2D5685246Q37997025-EB216355-8087-4399-AF65-E3480097EB31Q38164685-FA508241-4507-451C-95DF-23178045F01DQ38247400-4C47AB98-6888-4016-AF6A-DF6A919E9661Q38907793-7655A455-4813-4A9C-828D-94D82D3C4D70Q40280282-44777153-DF43-479F-AB1D-DEEF7F390DADQ42099202-695374D7-005A-4EB3-9280-D38DA2D52F23Q43947407-F944292B-320C-428E-B73B-66B0D50454B1Q46027436-4BE2F53A-39F2-4A85-9E5F-68354A5FE15AQ46968665-B997018D-89C7-4584-98C8-026D2933FC60Q47223964-3A907BA7-AD9D-40E8-9037-08A6A0E3D909
P2860
The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
The pharmacokinetics of daptom ...... and matched nonobese subjects.
@en
The pharmacokinetics of daptom ...... and matched nonobese subjects.
@nl
type
label
The pharmacokinetics of daptom ...... and matched nonobese subjects.
@en
The pharmacokinetics of daptom ...... and matched nonobese subjects.
@nl
prefLabel
The pharmacokinetics of daptom ...... and matched nonobese subjects.
@en
The pharmacokinetics of daptom ...... and matched nonobese subjects.
@nl
P2860
P356
P1476
The pharmacokinetics of daptom ...... and matched nonobese subjects.
@en
P2093
Barry H Dvorchik
David Damphousse
P2860
P356
10.1177/0091270004269562
P577
2005-01-01T00:00:00Z